The Massachusetts man who received the world’s first successful transplant of a genetically engineered pig kidney has died less than two months after the procedure, sources told NewsCenter 5. Richard Slayman, of Weymouth, underwent a surgery at Massachusetts General Hospital on March 16. and received a pig kidney with 69 genomic changes. The 62-year-old was released from Mass General on April 3 after weeks of recovery and said he was leaving the hospital “with one of the cleanest bills I’ve had in a hospital.” Sources said there was no indication that Slayman’s death was transplant-related. Slayman, who had lived with Type 2 diabetes and hypertension for many years, was suffering from end-stage kidney disease at the time of his death. the pig kidney transplant He had previously received a kidney transplant from a deceased human donor in December 2018 after being on dialysis seven years previously. His transplanted human kidney showed signs of failure about five years later. and Slayman returned to dialysis in May 2023. After returning to dialysis, Slayman experienced recurring problems with dialysis vascular access complications requiring biweekly hospital visits for decoagulation and surgical revisions. a common problem among dialysis patients that had a significant impact on his quality of life. Slayman said his nephrologist and the team at MGH Transplant Center suggested a pig kidney transplant, carefully explaining the pros and cons of that procedure. “I saw it not only as a way to help myself, but also as a way to give hope to the thousands of people who need a transplant to survive,” Slayman said shortly after the procedure. The pig kidney was provided by eGenesis of Cambridge, Massachusetts, from a pig donor that was genetically modified using technology to remove harmful porcine genes and add some human genes to improve its compatibility with humans. Mass General also said that scientists deactivated endogenous porcine retroviruses in the pig donor to eliminate any risk of infection in humans. The procedure was carried out under a single FDA expanded access protocol – known as compassionate use – granted to a single patient or group of patients with serious, potentially serious diseases or conditions. fatalities to gain access to experimental treatments or trials when no comparable treatment options or therapies exist. Previous coverage:
The Massachusetts man who received the world’s first successful transplant of a genetically engineered pig kidney has died less than two months after the procedure, sources tell NewsCenter 5.
Richard Slayman, of Weymouth, underwent surgery at Massachusetts General Hospital on March 16 and received a pig kidney with 69 genomic changes.
The 62-year-old was released from Mass General on April 3 after weeks of recovery and said he was leaving the hospital “with one of the cleanest bills I’ve had in a long time.” .
Sources said there was no indication Slayman’s death was related to the transplant.
Slayman, who had lived with Type 2 diabetes and hypertension for many years, was suffering from end-stage kidney disease at the time of the pig kidney transplant. He had previously received a kidney transplant from a human donor who died in December 2018 after being on dialysis seven years previously.
His transplanted human kidney showed signs of failure approximately five years later and Slayman returned to dialysis in May 2023. After resuming dialysis, Slayman experienced recurring dialysis vascular access complications requiring visits to the hospital every two weeks for decoagulation and surgical revisions, a common problem. problem in dialysis patients that had a significant impact on their quality of life.
Slayman said his nephrologist and the team at MGH Transplant Center suggested a pig kidney transplant, carefully explaining the pros and cons of that procedure.
“I saw it not only as a way to help myself, but also as a way to give hope to the thousands of people who need a transplant to survive,” Slayman said shortly after the procedure. .
The pig kidney was provided by eGenesis of Cambridge, Massachusetts, from a pig donor that was genetically modified using technology to remove harmful porcine genes and add some human genes to improve its compatibility with humans. Mass General also said that scientists deactivated endogenous porcine retroviruses in the pig donor to eliminate any risk of infection in humans.
The procedure was carried out under a single FDA expanded access protocol – known as compassionate use – granted to a single patient or group of patients with serious diseases or conditions affecting endangering life to gain access to experimental treatments or trials when no comparable treatment options or therapies exist. exist.
Previous coverage:
News Source : www.wcvb.com
Gn Health
